Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages

  Van Der Veldt, Astrid A M ^a   Vroling, Laura ^a   De Haas, Richard R ^a   Koolwijk, Pieter ^a   Van Den Eertwegh, Alfons J M ^a   Haanen, John B A G ^b   Van Hinsbergh, Victor W M ^a   Broxterman, Henk J ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

angiogenesis; circulating angiopoietin 2; endothelial cell activation; renal cell cancer; soluble intercellular cell adhesion molecule 1; soluble Tie 2; soluble vascular cell adhesion molecule 1; sunitinib; vascular endothelial growth factor; von Willebrand factor

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; SUNITINIB; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES;

EID: 84862541602     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26456     Document Type: Article

References (46)

1. van der Veldt AA, Haanen JB, van den Eertwegh AJ, Boven E,. Targeted therapy for renal cell cancer: current perspectives. Discov Med 2010; 10: 394-405.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24. (Pubitemid 46089672)
3. Chow LQM, Eckhardt SG,. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-96. (Pubitemid 350002890)
4. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, van den Beldt K, Qian CN, Teh BT,. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010; 70: 1053-62.
5. Brugarolas J,. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007; 356: 185-7.
6. Kerbel RS,. Tumor Angiogenesis. N Engl J Med 2008; 358: 2039-49. (Pubitemid 351656458)
7. Ferrara N, Davis-Smyth T,. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25. (Pubitemid 27076453)
8. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991; 138: 213-21.
9. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W, Thurston G, Augustin HG,. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103: 4150-6. (Pubitemid 38685356)
10. Findley CM, Cudmore MJ, Ahmed A, Kontos CD,. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2007; 27: 2619-26. (Pubitemid 350158914)
11. Kim I, Moon SO, Hoon Kim S, Jin Kim H, Soon Koh Y, Young Koh G,. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; 276: 7614-20.
12. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A, Bundred NJ,. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000; 92: 1329-36. (Pubitemid 30660593)
13. Hoffmann R, Franzke A, Buer J, Sel S, Oevermann K, Duensing A, Probst M, Duensing S, Kirchner H, Ganser A, Atzpodien J,. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer 1999; 79: 1742-5. (Pubitemid 29132298)
14. Santarosa M, Favaro D, Quaia M, Spada A, Sacco C, Talamini R, Galligioni E,. Expression and release of intercellular adhesion molecule-1 in renal-cancer patients. Int J Cancer 1995; 62: 271-5.
15. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60. (Pubitemid 27450643)
16. van der Veldt AA, de Boer M, Boven E, Eringa EC, van den Eertwegh AJ, van Hinsbergh VW, Smulders YM, Serné EH,. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anti-Cancer Drugs 2010; 21: 439-46.
17. Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van Hinsbergh VW, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009; 12: 69-79.
18. van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD,. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008; 14: 5884-92.
19. van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB,. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008; 99: 259-65.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG,. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16. (Pubitemid 30099779)
21. Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J,. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009; 27: 533-9.
22. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E,. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 2008; 14: 2431-6. (Pubitemid 351551077)
23. Green D, McMahon B, Foiles N, Tian L,. Measurement of hemostatic factors in EDTA plasma. Am J Clin Pathol 2008; 130: 811-5.
24. van der Heijden M, Pickkers P, van Nieuw Amerongen GP, van Hinsbergh VW, Bouw MP, van der Hoeven JG, Groeneveld AB,. Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. Intensive Care Med 2009; 35: 1567-74.
25. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M,. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96. (Pubitemid 34032623)
26. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63.
27. Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, et al. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res 2000; 6: 4697-704. (Pubitemid 32110407)
28. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D,. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001; 7: 1992-7. (Pubitemid 32994837)
29. Kontovinis L, Papazisis K, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris A,. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009; 9: 82.
30. Currie MJ, Gunningham SP, Turner K, Han C, Scott PA, Robinson BA, Chong W, Harris AL, Fox SB,. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 2002; 198: 502-10. (Pubitemid 35447003)
31. Rodins K, Cheale M, Coleman N, Fox SB,. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas. Clin Cancer Res 2002; 8: 1075-81.
32. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ,. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8. (Pubitemid 29309448)
33. Visconti RP, Richardson CD, Sato TN,. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA 2002; 99: 8219-24. (Pubitemid 34651033)
34. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG,. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009; 15: 1384-92.
35. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 2010; 103: 1407-14.
36. Zhou Q, Guo P, Gallo JM,. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008; 14: 1540-9. (Pubitemid 351413939)
37. Xu L, Duda DG, Di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1{alpha}, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009; 69: 7905-10.
38. de Primo S, Bello C, Smeraglia J, Baum C, Spinella D, Rini B, Michaelson MD, Motzer R,. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5: 32.
39. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS,. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069-74. (Pubitemid 350210993)
40. Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, Wasman J, Hartman P, Jesberger J, Dumadag L, Hohler E, Leeming R, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 2009; 15: 3583-90.
41. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH,. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009; 27: 6006-11.
42. Shen BQ, Lee DY, Zioncheck TF,. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999; 274: 33057-63. (Pubitemid 129535347)
43. de Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, Jr, Shin WS, Liao JK,. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-8.
44. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6: 507-16. (Pubitemid 39469986)
45. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27: 3557-65.
46. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010; 16: 3044-56.